

Sample Received: **April 15, 2026**

COA Issued: **June 5, 2026**

PRODUCT INFORMATION

Vendor: Neurovia	Sample Name: Gut Inflammation	Sample Type: Capsule	Lot Number: GUTCAP4-2026	MW (g/mol): 342.2, 725.8, 1419, 4964
----------------------------	---	--------------------------------	------------------------------------	--

ANALYTICAL METHODS

Identity: Confirmed via MALDI-MS

Purity: RP-HPLC (214 nm)




Content: HPLC quantitation

TEST RESULTS

Specification	Result	Method	Status
Identity: Gut Inflammation (BPC-157, KPV, TB500, Larazotide)	BPC-157, KPV, TB500, Larazotide	MALDI-MS	✓ Conforms
Content		HPLC Quantitation	✓ Conforms
Overall Purity	99.6%	RP-HPLC (214 nm)	✓ Conforms
Heavy Metals	<0.001 ppm	<USP231>	✓ Conforms
Endotoxin	<0.05 EU/mL	<USP85>	✓ Conforms

ANALYTICAL DATA

HPLC Chromatogram (Retention Time: 6.517, 7.958, 8.883 min)



Certification: This COA confirms that the tested material meets or exceeds Bioviridian's analytical quality specifications for peptide research use.

Visit: <https://bioviridians.com/coa-search.html>



Shane Straight
Shane Straight, M.S.
 Principal Chemist, Bioviridian Inc.